CIK 0001649989
- Non-accelerated filer
- Smaller reporting company
Outlook Therapeutics, Inc.
Sign in to watch- Ticker
- OTLK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 383982704
- Phone
- +1 609-619-3990
- Business address
- 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
- Former names
- Oncobiologics, Inc.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 10,000 shares at $1.82 ($18,200)
- 4 Open-market buy Director bought 10,000 shares at $1.82 ($18,200)
- 4 Open-market buy CEO, Pres, CFO, Treas & Secy bought 10,000 shares at $1.83 ($18,300)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Commercial Officer sold 8,554 shares at $2.09 ($17,861)
- 4 Open-market sale Chief Operating Officer sold 15,900 shares at $2.09 ($33,199)
- 4 Open-market sale Chief Commercial Officer sold 56,973 shares at $2.55 ($145,281)
- 4 Open-market sale Chief Operating Officer sold 63,700 shares at $2.55 ($162,435)
- 4 Grant or award Director acquired 1,013,627 shares (grant or award)
Page 7 of 16 · 305 filings